These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 23619309)
1. The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials. Haen SP; Rammensee HG Curr Opin Immunol; 2013 Apr; 25(2):277-83. PubMed ID: 23619309 [TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy: new insights]. Geissler M; Weth R Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040 [TBL] [Abstract][Full Text] [Related]
3. Current developments in cancer vaccines and cellular immunotherapy. Ribas A; Butterfield LH; Glaspy JA; Economou JS J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342 [TBL] [Abstract][Full Text] [Related]
4. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Sensi M; Anichini A Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217 [TBL] [Abstract][Full Text] [Related]
5. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccines for cancer immunotherapy. Timmerman JM; Levy R Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291 [TBL] [Abstract][Full Text] [Related]
7. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Speiser DE; Romero P Semin Immunol; 2010 Jun; 22(3):144-54. PubMed ID: 20413326 [TBL] [Abstract][Full Text] [Related]
9. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
10. [New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes]. Kawakami Y Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2536-44. PubMed ID: 9922678 [No Abstract] [Full Text] [Related]
11. Non-traditional immunogens and their application to immunotherapy. Chatterjee M; Tainsky MA Curr Opin Mol Ther; 2008 Feb; 10(1):62-7. PubMed ID: 18228183 [TBL] [Abstract][Full Text] [Related]
12. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]
13. [Identification of cancer antigens of relevance for specific cancer immunotherapy]. van den Eynde B Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273 [TBL] [Abstract][Full Text] [Related]
14. How to analyze ex vivo T-cell responses in cancer patients. Nagorsen D; Marincola FM In Vivo; 2002; 16(6):519-25. PubMed ID: 12494896 [TBL] [Abstract][Full Text] [Related]
15. RNA pulsed dendritic cells: an approach for cancer immunotherapy. Garg NK; Dwivedi P; Prabha P; Tyagi RK Vaccine; 2013 Feb; 31(8):1141-56. PubMed ID: 23306369 [TBL] [Abstract][Full Text] [Related]
16. Telomerase as a universal tumor antigen for cancer vaccines. Beatty GL; Vonderheide RH Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939 [TBL] [Abstract][Full Text] [Related]
17. Human cancer regression antigens. Kvistborg P; van Buuren MM; Schumacher TN Curr Opin Immunol; 2013 Apr; 25(2):284-90. PubMed ID: 23566921 [TBL] [Abstract][Full Text] [Related]